tbuckley/cabot-search huggingface dataset:
Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2019
Authors: Raf Bisschops, James E. East, Cesare Hassan, Yark Hazewinkel, Michał F. Kamiński, Helmut Neumann, Maria Pellisé, Giulio Antonelli, Marco Bustamante Balen, Emmanuel Coron, Georges Cortas, Marietta Iacucci, Mori Yuichi, Gaius Longcroft-Wheaton, Serguei Mouzyka, Nastazja Pilonis, Ignasi Puig, Jeanin E. van Hooft, Evelien Dekker
Journal: Endoscopy (2019)

Main Recommendations 1 ESGE suggests that high definition endoscopy, and dye or virtual chromoendoscopy, as well as add-on devices, can be used in average risk patients to increase the endoscopist’s adenoma detection rate. However, their routine use must be balanced against costs and practical considerations. Weak recommendation, high quality evidence. 2 ESGE recommends the routine use of high definition systems in individuals with Lynch syndrome. Strong recommendation, high quality evidence. 3 ESGE recommends the routine use, with targeted biopsies, of dye-based pancolonic chromoendoscopy or virtual chromoendoscopy for neoplasia surveillance in patients with long-standing colitis. Strong recommendation, moderate quality evidence. 4 ESGE suggests that virtual chromoendoscopy and dye-based chromoendoscopy can be used, under strictly controlled conditions, for real-time optical diagnosis of diminutive (≤ 5 mm) colorectal polyps and can replace histopathological diagnosis. The optical diagnosis has to be reported using validated scales, must be adequately photodocumented, and can be performed only by experienced endoscopists who are adequately trained, as defined in the ESGE curriculum, and audited. Weak recommendation, high quality evidence. 5 ESGE recommends the use of high definition white-light endoscopy in combination with (virtual) chromoendoscopy to predict the presence and depth of any submucosal invasion in nonpedunculated colorectal polyps prior to any treatment. Strong recommendation, moderate quality evidence. 6 ESGE recommends the use of virtual or dye-based chromoendoscopy in addition to white-light endoscopy for the detection of residual neoplasia at a piecemeal polypectomy scar site. Strong recommendation, moderate quality evidence. 7 ESGE suggests the possible incorporation of computer-aided diagnosis (detection and characterization of lesions) to colonoscopy, if acceptable and reproducible accuracy for colorectal neoplasia is demonstrated in high quality multicenter in vivo clinical studies. Possible significant risks with implementation, specifically endoscopist deskilling and over-reliance on artificial intelligence, unrepresentative training datasets, and hacking, need to be considered. Weak recommendation, low quality evidence.
JAAD Case Reports Article List
Authors: Michael Pelster, Sapna Amin, Simon Yoo, Haya Azouz, Haneen Salah, Saad Al-Ajlan, Mohammad Badran, Jamal Saleh, Linda Lee, Stefan Schieke, Paul Hosking, Sam Hwang, Anh Pham, James Dinulos, Timothy Quinn, Audrey Jacobsen, John Strasswimmer
Journal: Journal of the American Academy of Dermatology (2016)
52-Week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants
Authors: W. Reinisch, W. J. Sandborn, A. Kumar, P. F. Pollack, A. Lazar, R. B. Thakkar
Journal: Gut (2011)

<h3>Introduction</h3> We report week-52 results from an open-label extension that assessed the efficacy and safety of adalimumab (ADA) in anti-TNF–naïve patients with moderately to severely active ulcerative colitis (UC). <h3>Methods</h3> Patients were adults with UC (Mayo scores ≥6 points and endoscopic subscores ≥2 points) despite treatment with corticosteroids and/or immunosuppressants. After an 8-week, randomised, placebo-controlled period, patients could enter an open-label extension to receive ADA 40 mg every other week (eow) as maintenance therapy through week 52. Data were analyzed with non-responder imputation (NRI); missing scores and values after adjustment to weekly dosing (for flares/non-response) were imputed as treatment failures. Modified NRI (mNRI) analyses (post-hoc), which did not count patients who dose escalated as failures, and as-observed analyses were also performed. <h3>Results</h3> Of 390 patients in the primary analysis population, 360 received open-label ADA eow and 117 had their dosages increased to weekly ADA. Mean/median changes in Mayo (0–12) and partial Mayo (0–9) scores from baseline to week 52 (observed values, N=274) were –5.0/–5.0 and –3.7/–4.0, respectively (all p&lt;0.001). The table 1 summarises rates of clinical remission and other secondary end points at week 52. Remission rates at week 52 were 25.6% (NRI) and 29.5% (mNRI). No deaths or cases of tuberculosis were reported. <h3>Conclusion</h3> Treatment with open-label ADA 40-mg eow/weekly generally maintained clinical remission and other efficacy end points in patients with moderately to severely active UC. The safety profile in UC was consistent with the known safety profile of ADA.
Temporal and spatial systolic analysis of myocardial velocities in ischaemic heart disease: Role of the different myocardial layers Pedro Marcos-Alberca, Miguel A. Garc�a-Fern�ndez, Manuel Desco, Mar�a J. Ledesma, Andr�s Santos, Mar Moreno, Javier Bermejo, Norberto Malpica, Jos� C. Antoranz. Hospital Gregorio Mara��n, Madrid, Spain
Journal: Journal of the American College of Cardiology (2001)
American Cancer Society National Conference on Gynecologic Cancer—1980
Journal: JNCI Journal of the National Cancer Institute (1980)

American Cancer Society National Conference on Gynecologic Cancer—1980 Get access JNCI: Journal of the National Cancer Institute, Volume 64, Issue 3, March 1980, Page 690, https://doi.org/10.1093/jnci/64.3.690-c Published: 01 March 1980
MICHIGAN STATE BOARD OF HEALTH.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A SCARIFIER FOR SKIN TESTS AND VACCINATIONS
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Changes in conditional survival (CS) in de novo metastatic urothelial carcinoma (mUC): A Surveillance, Epidemiology, and End Results (SEER) database analysis.
Authors: Kara DeWalt, Nicholas J. Vogelzang, Rebecca A. Nelson, Sumanta Kumar Pal
Journal: Journal of Clinical Oncology (2014)

4548 Background: No agents have been approved by the US FDA for the 2nd-line treatment of mUC. Still, many US patients receive treatment in this setting, calling upon phase II datasets emerging over the past decade for payor justification. While the cumulative disease-specific survival (DSS) for mUC may not change on account of this practice, assessment of CS may allow greater focus on patients who receive post-1st-line therapies. Methods: The SEER database was queried to compare the DSS and CS of de novo mUC patients diagnosed from 1994-2000 (T1) and 2001-2009 (T2). The year 2000 was chosen as a cutoff due to multiple phase II datasets for 2nd-line regimens published subsequent to this date. DSS in subgroups divided by time period were summarized using the Kaplan-Meier method and compared using the log-rank test. The chi-square test was used to compare the CS of subgroups divided time period at annual intervals up to 5 years. Multivariate analysis (MVA) was performed to determine the relationship between DSS and clinicopathologic/treatment-related variables. Results: Outcomes were assessed for a total of 4,465 pts, with 1,155 diagnosed during T1 and 3,310 diagnosed during T2. Mean age of the overall cohort was 70, and the majority of patients had poorly differentiated or undifferentiated tumors. For the overall cohort, 1-year DSS for T1 and T2 were 23% and 25% (P=NS). At landmark analyses at 1 yr, 2 yrs and 3 yrs following diagnosis, 1-yr CS in groups diagnosed during T1 and T2 were 46% and 39%, 71% and 68%, and 76% and 78%, respectively (P=NS for each comparison). On MVA, time period of diagnosis (T1 vs T2) was not a significant predictor of DSS. Instead, older age (>65) and undifferentiated histology were predictive of poorer DSS, while use of radiation or surgery were associated with improved DSS. Conclusions: Multiple published phase II studies emerging over the past decade have been used to justify use of post-1st-line therapies for mUC to payors. Our assessment of CS should better account for the impact of these therapies as compared to cumulative DSS. The lack of improvement CS calls into question the impact post-1st-line therapies have had on the natural history of mUC.
BUREAU OF LEGAL MEDICINE AND LEGISLATION
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
index to advertisers
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Weight Gain Associated With Intensive Therapy in the Diabetes Control and Complications Trial
Journal: Diabetes Care (1988)

Identifiable risks such as increased frequency of hypoglycemia accompany the treatment of insulindependent diabetes mellitus (IDDM) with intensive insulin therapy. During yr 1 of the Diabetes Control and Complications Trial (DCCT), weight gain was identified as a sequela of intensive insulin therapy. The DCCT is a multicenter controlled clinical trial designed to determine the long-term effects of two different diabetes treatment regimens on the early vascular and neurologic complications of IDDM. Subjects randomized to the intensive treatment regimen gained significantly more weight (5.1 ± 4.6 kg) than the standard treatment subjects (2.4 ± 3.7 kg, P &amp;lt; .0001) during the 1st yr of therapy. Higher baseline HbA1c levels and greater decrements in HbA1c during intensive therapy were both associated with greater weight gain. In addition, intensively treated subjects with one or more severe hypoglycemic episodes gained more weight than the intensively treated subjects with no severe episodes. There was no relationship between reported caloric intake or exercise level and the weight changes. These data suggest that improved utilization of calories through a decrease in glycosuria and perhaps other mechanisms led to the weight gain in the intensively treated subjects. The results from the 1st yr of experience in the DCCT indicate that weight gain accompanies efforts to lower blood glucose levels with intensive insulin therapy. Because of the potential adverse consequences of undesirable weight gain, including diminished long-term compliance with therapy and an adverse effect on blood pressure and lipid status, efforts to prevent undesirable weight gain in the intensively treated group of the DCCT are being pursued.
Fulminant hepatic failure: Summary of a workshop*1
Authors: J HOOFNAGLE
Journal: Hepatology (1995)

Fulminant hepatic failure (FHF) is defined by the appearance of severe liver injury with hepatic encephalopathy in a previously healthy person. There are an estimated 2,000 cases of FHF in the United States yearly, representing 0.1% of all deaths and, perhaps, 6% of liver-related deaths. The causes of FHF are many, the chief ones in the United States being hepatitis A; B; non-A, non-B and drug induced liver disease. There are no specific therapies for FHF, however, liver transplantation is recommended for situations in which spontaneous recovery appears unlikely. Factors that are valuable in assessing the likelihood of spontaneous recovery are static features such as patient age and etiology of FHF and dynamic features including encephalopathy grade, prothrombin time, and serum bilirubin. Presently, approximately 7% of all liver transplants are done for FHF and the 1-year patient survival rates average 63%, somewhat less than survival rates for nonfulminant liver disease, averaging 78%. The management of patients with FHF is challenging, particularly important being monitoring and early treatment of infections, hemodynamic abnormalities, and brain edema. Innovative approaches to management and therapy include use of cytoprotective or antiviral medications, hepatic support systems, extracorporeal liver support, hepatocyte transplantation, auxiliary liver transplantation, and xenotransplantation. None of these are of proven benefit, but many are promising as a means to support the patient with FHF until spontaneous recovery occurs or a suitable liver graft is available for transplantation.
Environmental Contaminants and Intestinal Function
Authors: John G. Banwell
Journal: Environmental Health Perspectives (1979)

The environmental contaminants which have their major effects on the small intestine may be classified into five major categories: (1) bacterial, viral, and parasitic agents, (2) food and plant substances, (3) environmental and industrial products, (4) pharmaceutical agents, and (5) toxic agents whose metabolic effects are dependent on interreaction with intestinal bacterial flora, other physical agents (detergents), human intestinal enzyme deficiency states, and the nutritional state of the host. Bacterial, viral, and parasitic agents are the most important of all such agents, being responsible for significant mortality and morbidity in association with diarrheal diseases of adults and children. Several plant substances ingested as foods have unique effects on the small bowel as well as from contaminants such as fungi on poorly preserved grains and cereals. Environmental and industrial products, in spite of their widespread prevalence in industrial societies as contaminants, are less important unless unexpectedly intense exposure occurs to the intestinal tract. Pharmaceutical agents of several types interreact with the small bowel mucosa causing impairment of transport processes for fluid and electrolytes, amino acid, lipid and sugars as well as vitamins. These interreactions may be dependent on bacterial metabolic activity, association with detergents, mucosal enzyme deficiency state (disaccharidases), and the state of nutrition of the subject.
Relapse of herpes simplex encephalitis after conventional acyclovir therapy
Authors: K. E. VanLandingham
Journal: JAMA (1988)

Acyclovir sodium is the drug of choice for the treatment of herpes simplex encephalitis. We treated an immunocompetent patient with a ten-day course of intravenous acyclovir sodium at the recommended dosage of 10 mg/kg every eight hours for clinically apparent herpes simplex encephalitis. After marked improvement, his condition deteriorated four days after completing acyclovir therapy. A subsequent brain biopsy specimen disclosed acyclovir-sensitive herpes simplex virus type 1. A longer duration of acyclovir therapy (14 to 21 days) should be considered for treating herpes simplex encephalitis. (<i>JAMA</i>1988;259:1051-1053)
Ethics
Authors: E. D. Pellegrino
Journal: JAMA (1989)

This article will focus on the related issues of euthanasia and fetal tissue research. Both raise fundamental questions about the meaning of human life and have occasioned intensive debates because of the moral heterogeneity of our society. Active, voluntary euthanasia is the deliberate ending of the life of a terminally ill patient who requests it. Most recently, the subject has been thrust into public consciousness by reports of its practice in the Netherlands,<sup>1</sup>by the move to place the "Humane and Dignified Death Initiative"<sup>2</sup>on the 1988 California ballot, byThe Journal'spublication of "It's Over, Debbie,"<sup>3</sup>and by reports of the Rosier case in Florida, where a physician-husband was acquitted in the mercy killing of his wife (<i>New York Times</i>, December 2, 1988;sect A:20). It is increasingly apparent that many people believe euthanasia to be morally licit and favor its legalization. In California, 175 000 people
Heart research efforts aim at fairness to women in terms of causes, care of cardiac disorders
Authors: M. F. Goldsmith
Journal: JAMA (1990)

"WHY CAN'T a woman be more like a man?" wondered<i>My Fair Lady's</i>Professor Henry Higgins. If she were, life would be simpler for cardiologists. Data amassed for many years about the causes and care of heart disease in men do not compute when it comes to understanding the problem in women, researchers have realized only recently (<i>JAMA</i>. 1990;263:1049-1050). Despite its later advent in women, cardiovascular disease is a killer of both sexes. Just 2 years ago, under the presidency of Bernadine Healy, MD, chair of the Cleveland Clinic Foundation's Research Institution (and the latest person named to head the National Institutes of Health), the American Heart Association launched its first major effort to foster research into the specific factors that influence heart disease in women. This year in Dallas, Tex, at the 63rd Scientific Sessions, several presentations addressed the issue. <h3>Postmenopausal Vulnerability</h3> Seeking to clarify the role of female
Heart Disease
Authors: Mark D. Altschule
Journal: JAMA (1988)

This remarkable book is now in its second edition and will need to go into several more, since it is in large measure a review of physiological literature bearing on clinical cardiology. One of its virtues is that the book is by one person, in contradistinction to works of similar size that have been created by many authors, each of whom may have been made an authority on some narrow subject by virtue of being one of half a dozen authors on a published article. Silber's book has been created and organized with the views of one man of massive intellectual capacity and wide-reaching and extraordinary organizational ability. The book has thousands of references and therein, paradoxically, lies its main fault. The references usually refer to the conclusions of the articles cited and not to their data. As experienced workers in any branch of laboratory science must know, the conclusions
A Rare Genetic Polymorphism In C5 Confers Poor Response To The Anti-C5 Monoclonal Antibody Eculizumab In 11 Japanese Patients With PNH
Authors: Jun-ichi Nishimura, Masaki Yamamoto, Shin Hayashi, Kazuma Ohyashiki, Kiyoshi Ando, Hideyoshi Noji, Kunio Kitamura, Tetsuya Eto, Toru Takahashi, Masayoshi Masuko, Takuro Matsumoto, Yuji Wano, Tsutomu Shichishima, Hirohiko Shibayama, Masakazu Hase, Li Lan, Krista Johnson, Paul Tamburini, Johji Inazawa, Taroh Kinoshita, Yuzuru Kanakura
Journal: Blood (2013)
First International Symposium on Hl-A and Disease
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article First International Symposium on Hl-A and Disease Get access JNCI: Journal of the National Cancer Institute, Volume 56, Issue 2, February 1976, Page 453, https://doi.org/10.1093/jnci/56.2.453 Published: 01 February 1976